Trial intelligence / Profile preview

Taxotere in hormone-independent prostate cancer

2005-001873-91Phase 4Completed

Sponsor
Sanofi
Start
Jul 2005
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by Sanofi. Primary endpoints: Treatment tolerability and adverse event assessment and Treatment outcomes by WHO response evaluation. Started Jul 2005; status: completed.

02

Drugs

docetaxel
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2005-001873-91.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-001873-91.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call